A phase II study evaluating efficacy and safety of Ipilimumab and Nivolumab with neoadjuvant weekly paclitaxel after anthracycline based chemotherapy in high-risk primary triple negative breast cancer, followed by definitive surgery and one year total duration of Nivolumab (BCT 1702 CHARIOT)
收藏DataCite Commons2024-08-21 更新2024-07-13 收录
下载链接：
https://doi.breastcancertrials.org.au/100
下载链接
链接失效反馈官方服务：
资源简介：
HeSANDA 1.0.0
提供机构：
Breast Cancer Trials (BCT)
创建时间：
2023-12-05
